Semaglutide
Semaglutide is an FDA-approved GLP-1 receptor agonist sold as Ozempic and oral Rybelsus for type 2 diabetes and as injectable Wegovy and, as of a December 2025 approval, an oral tablet form of Wegovy for chronic weight management.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1) that has been modified with a fatty-diacid side chain enabling albumin binding, which slows enzymatic degradation and renal clearance. It binds and activates the GLP-1 receptor on pancreatic beta cells, vagal afferent neurons, and hypothalamic appetite centers (notably the arcuate nucleus), stimulating glucose-dependent insulin secretion while suppressing glucagon release. Central GLP-1 receptor activation reduces food intake and reward-driven eating, while delayed gastric emptying contributes to increased satiety.
Typical results seen in research
In the pivotal STEP 1 trial, participants without diabetes lost an average of about 14.9% of body weight over 68 weeks of treatment versus roughly 2.4% with placebo. The cardiovascular outcomes trial SELECT demonstrated a roughly 20% relative reduction in major adverse cardiovascular events in overweight/obese adults with established cardiovascular disease but without diabetes. As a diabetes therapy (Ozempic/Rybelsus), semaglutide produces clinically meaningful reductions in HbA1c alongside weight loss.
How it’s commonly used
Semaglutide is administered either via subcutaneous injection using a prefilled pen (Ozempic, Wegovy) or taken orally as a tablet (Rybelsus, and the newer oral Wegovy formulation). It is used under medical supervision alongside a reduced-calorie diet and increased physical activity, with the injectable dose gradually titrated upward by a prescriber over time.
- New England Journal of Medicine · 2021 Once-Weekly Semaglutide in Adults with Overweight or Obesity
- New England Journal of Medicine · 2023 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
- Diabetes, Obesity and Metabolism · 2022 Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
- Semaglutide Extends Lifespan and Improves Healthspan in Landmark Mouse Aging Study —
- BioLife Wins US Patent for Effervescent Oral Semaglutide Delivery Technology —
- Semaglutide Linked to Lower Psychiatric Hospitalization Risk in Large Bipolar Disorder Study —